MSP Recovery (NASDAQ:MSPR – Get Free Report) and Fulgent Genetics (NASDAQ:FLGT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and price targets for MSP Recovery and Fulgent Genetics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MSP Recovery | 1 | 0 | 0 | 0 | 1.00 |
| Fulgent Genetics | 1 | 2 | 2 | 0 | 2.20 |
Fulgent Genetics has a consensus price target of $32.00, indicating a potential upside of 105.26%. Given Fulgent Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Fulgent Genetics is more favorable than MSP Recovery.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MSP Recovery | $9.81 million | 0.05 | -$360.50 million | ($572.83) | 0.00 |
| Fulgent Genetics | $322.67 million | 1.51 | -$60.51 million | ($1.96) | -7.95 |
Fulgent Genetics has higher revenue and earnings than MSP Recovery. Fulgent Genetics is trading at a lower price-to-earnings ratio than MSP Recovery, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
3.8% of MSP Recovery shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 50.5% of MSP Recovery shares are owned by insiders. Comparatively, 31.8% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
MSP Recovery has a beta of -2.9, indicating that its share price is 390% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Profitability
This table compares MSP Recovery and Fulgent Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MSP Recovery | -7,328.48% | -326.80% | -81.27% |
| Fulgent Genetics | -18.75% | -2.22% | -2.05% |
Summary
Fulgent Genetics beats MSP Recovery on 12 of the 14 factors compared between the two stocks.
About MSP Recovery
MSP Recovery, Inc. engages in the development of healthcare recoveries and data analytics software. It also focuses on the identification and recoveries of improper payments made by Medicare, Medicaid, and commercial insurance spaces using data and analytics. The company was founded by John H. Ruiz, Frank C. Quesada, and Diana Diaz on July 8, 2014 and is headquartered in Miami, FL.
About Fulgent Genetics
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
Receive News & Ratings for MSP Recovery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MSP Recovery and related companies with MarketBeat.com's FREE daily email newsletter.
